SCHEMBL6929441

SCHEMBL6929441

CCC(C)OP(=O)(O)c1cc2cc(S(N)(=O)=O)c(F)cc2[nH]c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926886 0.90 — —
SCHEMBL6926878 0.88 CA1 (0.36) —
SCHEMBL7198556 0.87 CA12 (0.33) —
SCHEMBL6928605 0.85 HPRT1 (0.31) —
SCHEMBL6926212 0.80 GRIN1 (0.33) —
SCHEMBL6927156 0.80 DAO (0.33) —
SCHEMBL6923316 0.80 GRIN1 (0.36) —
SCHEMBL7199614 0.79 EGLN1 (0.30) —
SCHEMBL6928590 0.78 DAO (0.46) —
SCHEMBL6929437 0.78 POLB (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596709-B1 For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea LES LABORATOIRES SERVIER (FR) 2003-07-22 — — US disclosed
US-6518258-B1 6-sulphamoyl -3-quinolyphosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2003-02-11 — — US disclosed
Send feedback